Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis.
NONMEM
nosocomial ventriculitis
population pharmacokinetics
vancomycin
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
27
10
2020
received:
15
07
2020
accepted:
05
11
2020
pubmed:
18
11
2020
medline:
21
9
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
To determine the distribution of vancomycin into the cerebrospinal fluid (CSF) in patients with external ventricular drain (EVD)-associated ventriculitis, the pharmacokinetics of vancomycin were evaluated and covariate relationships explored. For the population pharmacokinetic model patients were recruited in a neurocritical care unit at the University Hospital of Muenster in the period between January 2014 and June 2015. All patients had a clinical evidence of EVD-associated ventriculitis. Population pharmacokinetic analysis of vancomycin was performed using NONMEM. A total of 184 blood and 133 CSF samples were collected from 29 patients. The final population pharmacokinetic model is a three-compartment model with linear elimination. Creatinine clearance (Cl Based on our analysis, the dosing of vancomycin should be referred to the degree of inflammation (derived from the CSF lactate concentration) and renal function (derived from Cl
Sections du résumé
BACKGROUND
To determine the distribution of vancomycin into the cerebrospinal fluid (CSF) in patients with external ventricular drain (EVD)-associated ventriculitis, the pharmacokinetics of vancomycin were evaluated and covariate relationships explored.
METHODS
For the population pharmacokinetic model patients were recruited in a neurocritical care unit at the University Hospital of Muenster in the period between January 2014 and June 2015. All patients had a clinical evidence of EVD-associated ventriculitis. Population pharmacokinetic analysis of vancomycin was performed using NONMEM.
RESULTS
A total of 184 blood and 133 CSF samples were collected from 29 patients. The final population pharmacokinetic model is a three-compartment model with linear elimination. Creatinine clearance (Cl
CONCLUSION
Based on our analysis, the dosing of vancomycin should be referred to the degree of inflammation (derived from the CSF lactate concentration) and renal function (derived from Cl
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2502-2510Informations de copyright
© 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Chatzi M, Karvouniaris M, Makris D, et al. Bundle of measures for external cerebral ventricular drainage-associated ventriculitis. Crit Care Med. 2014;42(1):66-73.
Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2002;51:170-181. discussion 181-182
Humphreys H, Jenks P, Wilson J, et al. Surveillance of infection associated with external ventricular drains: proposed methodology and results from a pilot study. J Hosp Infect. 2017;95(2):154-160.
von Spreckelsen N, Jung N, Telentschak S, Hampl J, Goldbrunner R, Grau S. Current treatment concepts for iatrogenic ventriculitis: a nationwide survey in Germany. Acta Neurochir. 2018;160:505-508.
Tunkel AR, Hasbun R, Bhimraj A, et al. Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infec Dis. 2017;64:e34-e65.
May CC, Arora S, Parli SE, Fraser JF, Bastin MT, Cook AM. Augmented renal clearance in patients with subarachnoid hemorrhage. Neurocrit Care. 2015;23(3):374-379.
Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858-883.
Beach JE, Perrott J, Turgeon RD, Ensom MHH. Penetration of vancomycin into the cerebrospinal fluid: a systematic review. Clin Pharmacokinet. 2017;56(12):1479-1490.
Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986;11(4):257-282.
Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clinical Infectious Diseases. 2006;42(Suppl 1):S35-S39.
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309-332.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
Udy A, Boots R, Senthuran S, et al. Augmented creatinine clearance in traumatic brain injury. Anesth Analg. 2010;111(6):1505-1510.
Schobben F, van der Kleijn E. Drug determinations in body fluids by the enzyme multiplied immunoassay technique (EMIT®). Eur J Drug Metab Pharmacokinet. 1977;2:185-189.
Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11(2):371-380.
Beal SL, Sheiner LB. NONMEM users guide. 3rd ed. University of California Press; 1989. file:///C:/Users/User/Downloads/i%20(1).pdf
Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-257.
Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm. 1990;18(2):161-173.
Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463-1468.
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. Part 2: Introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2(4):e38-52.
Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221-234.
Brown PD, Davies SL, Speake T, Millar ID. Molecular mechanisms of cerebrospinal fluid production. Neuroscience. 2004;129(4):957-970.
Segal MB. Extracellular and cerebrospinal fluids. J Inherit Metab Dis. 1993;16(4):617-638.
Skipor J, Thiery J-C. The choroid plexus-cerebrospinal fluid system: undervaluated pathway of neuroendocrine signaling into the brain. Acta Neurobiol Exp. 2008;68(3):414-428.
Wright BLC, Lai JTF, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol. 2012;259(8):1530-1545.
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C. 2019. Therapeutic monitoring of vancomycin: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists [https://www.ashp.org/-/media/assets/policy-guidelines/docs/draft-guidelines/draft-guidelines-ASHP-IDSA-PIDS-SIDP-therapeutic-vancomycin.ashx].
Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62(2):e02042-17.
Donadello K, Roberts JA, Cristallini S, et al. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care. 2014;18(6):632-642.
Llopis-Salvia P, Jiménez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther. 2006;31(5):447-454.
Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60(3):265-275.
Dolton M, Xu H, Cheong E, et al. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns. 2010;36(4):469-476.
Sánchez JL, Dominguez AR, Lane JR, Anderson PO, Capparelli EV, Cornejo-Bravo JM. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48(8):525-533.
Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009;34(4):473-483.
Rall DP. Drug Entry into Brain and Cerebrospinal Fluid. Concepts in Biochemical Pharmacology. Handbook of Experimental Pharmacology. 28. 1. Berlin, Heidelberg: Springer Berlin Heidelberg; Handbuch der experimentellen Pharmakologie/Handbook of Experimental Pharmacology, 28/1. 1971:240-248.
Siegel GJ, Agranoff BW, Albers RW, Price D. Basic neurochemistry: Molecular, cellular and medical aspects. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999. https://www.ncbi.nlm.nih.gov/books/NBK20385/
Geraci JE, Heilman FR, Nichols DR, Wellman EW, Ross GT. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Antibiot Ann. 1956;90-106.
Leroux P, Howard MA, Richard Winn H. Vancomycin pharmacokinetics in hydrocephalic shunt prophylaxis and relationship to ventricular volume. Surg Neurol. 1990;34(6):366-372.
Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg. 2003;98(5):1040-1044.
Ricard J-D, Wolff M, Lacherade J-C, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis. 2007;44(2):250-255.
Albanèse J, Léone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44(5):1356-1358.
Viladrich PF, Gudiol F, Liñares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991;35(12):2467-2472.
Gerber J, Tumani H, Kolenda H, Nau R. Lumbar and ventricular CSF protein, leukocytes, and lactate in suspected bacterial CNS infections. Neurology. 1998;51(6):1710-1714.
Thomas L. Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 8th ed. Frankfurt/Main: Th-Books Verl.-Ges; 2012.
Curtis GDW, Slack MPE, Tompkins DE. Cerebrospinal fluid lactate and the diagnosis of meningitis. J Infect. 1991;3:159-165.
Lannigan R, MacDonald MA, Marrie TJ, Haldane EV. Evaluation of cerebrospinal fluid lactic acid levels as an aid in differential diagnosis of bacterial and viral meningitis in adults. J Clin Microbiol. 1980;11(4):324-327.
de Gatta MD, Revilla N, Calvo MV, Domínguez-Gil A, Navarro AS. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med. 2007;33:279-285.
Revilla N, Martín-Suárez A, Pérez MP, González FM, Fernández de Gatta MDM. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol. 2010;70(2):201-212.
Roberts JA, Taccone FS, Udy AA, Vincent J-L, Jacobs F, Lipman J. Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens. Antimicrob Agents Chemother. 2011;55(6):2704-2709.
Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2020;77:835-864.
Blassmann U, Hope W, Roehr AC, et al. CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. J Antimicrob Chemother. 2019;74(4):991-996.
Li X, Wu Y, Sun S, et al. Population pharmacokinetics of vancomycin in postoperative neurosurgical patients. J Pharm Sci. 2015;104(11):3960-3967.
Li X, Wu Y, Sun S, Zhao Z, Wang Q. Population pharmacokinetics of vancomycin in postoperative neurosurgical patients and the application in dosing recommendation. J Pharm Sci. 2016;105(11):3425-3431.